Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duration and Efficacy of MYDAYIS in Adult ADHD
NCT03945175Phase 3Completed
- Sponsor
- NYU Langone Health
- Start
- Jul 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of SHP465 mixed amphetamine salts in attention deficit hyperactivity disorder (ADHD), sponsored by NYU Langone Health. Started Jul 2020; status: completed.
02
Drugs
SHP465 mixed amphetamine salts
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03945175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945175.